Previous neuropathological studies have revealed that the corticolimbic system of schizophrenic patients expresses abnormal levels of various synaptic molecules, which are known to be influenced by the neuronal differentiation factors, neurotrophins. Therefore, we determined levels of neurotrophins and their receptors in the postmortem brains of schizophrenic patients and control subjects in relation to molecular impairments in schizophrenia. Among the neurotrophins examined, levels of brain-derived neurotrophic factor (BDNF) were elevated specifically in the anterior cingulate cortex and hippocampus of schizophrenic patients, but levels of nerve growth factors and neurotrophin-3 showed no change in any of the regions examined. In parallel, the expressions of TrkB receptor and calbindin-D, which are both influenced by BDNF, were reduced significantly in the hippocampus or the prefrontal cortex. However, neuroleptic treatment did not appear to mimic the neurotrophic change. Neither withdrawal of drug treatment in patients nor chronic administration of haloperidol to rats altered levels of BDNF. These findings suggest that neurotrophic abnormality is associated with the corticolimbic structures of schizophrenic patients and might provide the molecular substrate for pathological manifestations of the illness. Molecular Psychiatry (2000) 5, 293-300.
Introduction
Abnormal structural and neurochemical development, resulting in abnormal neural circuitry and function, has been implicated in schizophrenia. 1, 2 Recently, a family of neurotrophic factors, comprising nerve growth factor (NGF), BDNF, neurotrophin-3 (NT-3) and neurotrophin-4/5, have been suggested to be potent regulators of neuronal phenotypic differentiation and synaptic plasticity in mammals. [3] [4] [5] [6] In addition, there is growing evidence that these neurotrophins are involved in the cerebral structural organization such as the formation of the ocular dominance column, the whisker representation pads and neocortical layers. [7] [8] [9] Together with the findings that BDNF regulates phenotypic expressions of brain neurons, [10] [11] [12] [13] [14] [15] these observations imply that abnormal signals of neurotrophins could lead to the malformation of cortical circuitry or to the aberrant synaptic transmission of the mature brain, both of which seem to be comprised in the brain dysfunction of schizophrenics. To assess potential contribution of BDNF to such pathological phenotypes of schizophrenic patients, we quantitated levels of BDNF, together with other neurotrophins, NGF and NT-3, using two-site enzyme immunoassay (EIA) 16, 17 and attempted to correlate these findings with the expressions of BDNF receptors (TrkB) and calbindin D, which may reflect the activity of BDNF in patients. 18, 20 
Materials and methods

Human tissue sampling
Brain tissue was collected posthumously from 18 patients with chronic schizophrenia (10 men, eight women; mean age: 61.6 years; SD: 15.2) and from 36 controls (23 men, 13 women, mean age: 59.4 years; SD: 12.9) who had no history of neuropsychiatric disorders (Table 1 ). All the schizophrenics had taken typical antipsychotics for prolonged periods, but six of them had been off medication for at least 3 months before death. The diagnoses of schizophrenia corresponded to the DSM-IV categories (American Psychiatric Association, 1994). The prefrontal cortex was sampled from the dorsolateral prefrontal cortex (BA46) and the anterior cingulate from the area BA24. The hippocampal tissue taken did not include the surrounding entorhinal and parahippocampal areas. All the anatomical orientation was based on the Human Brain Atlas. 19 The families of the control and schizophrenic subjects provided written informed consent for the use of brain tissues as materials for the investigations. . 20 Homogenates were centrifuged for 20 min at 14 000 × g at 4°C, and supernatants were stored at −80°C until use. The protein contents of samples were determined using a Micro BCA kit (Pierce, Rockland, IL, USA) with bovine serum albumin as a standard. All the experiments were done under the authorization of the Niigata University Ethics Committee.
Neuroleptic treatment of animals
Male Wistar rats (initial weight 210-270 g) were housed in groups of three or four on a 12-h light-dark cycle with free access to food and water. Different groups of rats were treated orally with either haloperidol (target dose, 1.5 mg kg
) or vehicle as drinking water for 28 days. Haloperidol was dissolved in a minimal amount of acetic acid, diluted with distilled water, and pH-balanced with NaOH to give a final drinking solution of 0.025 mg ml −1 , pH 6.5. This treatment regimen resulted in plasma haloperidol concentrations of 4.8 ± 0.8 ng ml −1 (n = 6) after 28 days, equivalent to the therapeutic range for haloperidol in humans. Brains were removed rapidly from decapitated rats, and each brain region was dissected on ice. All the animal experiments were done according to the Animal Use and Care Committee guidelines of the Niigata University.
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Enzyme immunoassay Neurotrophin levels were measured by two-site enzyme immunoassay (EIA) as described previously. 16, 17 In brief, tissue extracts (10-100 l; duplicate) or neurotrophin standards (1-300 pg; triplicate) were loaded into the wells of EIA titer plates that had been coated with 100 ng well −1 anti-BDNF, anti-NGF or anti-NT-3 antibody (primary antibody). Biotinylated anti-BDNF, anti-NGF or anti-NT-3 antibody (secondary antibody; 10-30 ng ml ) was added to the wells, and then bound biotinylated secondary antibodies were detected using streptavidin-␤-galactosidase (1:10 000; Sigma). The activity of ␤-galactosidase retained in each well was measured by incubation with 200 mM 4-methylumbelliferyl-␤-d-galactosidase (MUG, Sigma). The amount of the fluorescent product was monitored by a Fluorolite-1000 fluorometer (Dynatech Laboratories, Chantilly, VA, USA) with excitation at 364 nm and emission at 448 nm. An average of two measurements of a sample was standardized by its protein concentration. Table 1 . *Significantly different from controls (ANOVA, P Ͻ 0.05). **Significantly different from controls (ANOVA, P Ͻ 0.01).
Figure 1
Neurotrophin levels in the brain of schizophrenic patients. Scatterplots display the variability and differences in the levels of BDNF, NGF and NT-3 between the schizophrenic and control subjects. Significantly different from controls (**P Ͻ 0.01, ANOVA with age as a covariate,***P Ͻ 0.001, one-way ANOVA). Clear diamonds, neuroleptic-withdrawn schizophrenics; solid diamonds, neuroleptic-treated schizophrenics; clear circles, controls; SCZ, schizophrenics; CON, controls; PFC, prefrontal cortex; ACC, anterior cingulate cortex; HIP, hippocampus; OCC, occipital cortex. Horizontal solid or dashed line represents a mean of values. Note: A sample, whose raw measurements varied significantly in a duplicated EIA, was not adopted as data. This is the reason why the number of samples differs among neurotrophins.
Western blot analysis
Relative levels of TrkB, calbindin-D and NSE were determined by Western blot analysis using methods similar to those described previously.
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Protein samples for Western blotting were prepared from the same tissue extracts for the two-site EIAs by denaturing them with 2% sodium dodecyl sulfate (SDS), separated by SDS-polyacrylamide gel electrophoresis (PAGE), and transferred to a nitrocellulose membrane (Schleicher and Schull, Dassel, Germany) by electrophoresis. The membrane was probed with anti-TrkB antibody (Novaris Japan, 1:1000), anti-calbindin-D antibody (Sigma, 1:1000) or anti-NSE antibody (Chemicon, Temecula, CA, USA; 1:2000). After extensive washing, the immunoreactivity on the membrane was detected with anti-rabbit/mouse immunoglobulin conjugated to horseradish peroxidase followed by chemiluminescence reaction (ECL kit; Amersham, UK). Densitometric quantitation of the band intensities was done, and each value was expressed as a percentage of the standard samples.
Statistical analysis
The potential confounding influences of age, sex and PMI upon neurotrophin and other protein levels were investigated using multiple regression. Changes in neurotrophin and other protein abundance associated with schizophrenia were then investigated by analysis of variance (ANOVA) with these factors as covariates where necessary and their correlation was examined by the Pearson's product moment (using SPSS 6.1J, SPSS Japan Inc, Tokyo, Japan). P Ͻ 0.05 was considered statistically significant. All values are presented as means ± SEM.
Results
Postmortem samples of these brain regions, and the occipital cortex as a control, were obtained randomly from 18 chronic schizophrenics (classified by DSM-IV), and from 36 age-matched controls who had no history of neuropsychiatric disorders (Table 1 ). There was a sampling difference of postmortem intervals (PMI) between the two groups, but all the other indices were similar ( Table 2) . We analyzed the difference in neurotrophin levels between the two groups and found that BDNF levels were significantly increased in the hippocampus and anterior cingulate cortex, but not in the frontal cortex or occipital cortex, of the schizophrenics in comparison with controls ( Figure 1a) . These differences were also shown to be significant by Friedman nonparametric analysis (data not shown). NGF levels tended to be increased in the hippocampus of the schizophrenics but not to a significant extent (P = 0.07, ANOVA) (Figure 1b) . NT-3 levels did not vary significantly between the two groups, although those in the hippocampus and anterior cingulate cortex were too low for EIA detection, and not subjected to statistical analysis (Figure 1c) . Multiple regression analysis revealed that PMI did not affect neurotrophin levels in any brain region in either the schizophrenics or control Molecular Psychiatry subjects. Thus, the difference in PMI appeared not to contribute to the BDNF increase (see details in Discussion). However, age was a contributor to the variances of the BDNF levels in the frontal and anterior cingulate cortices of schizophrenics (frontal, ␤ = −0.79, P = 0.02; anterior cingulate, ␤ = −0.52, P = 0.04), increasing age being associated with a reduction in BDNF levels, but not in the controls (frontal, ␤ = −0.34, P = 0.10; anterior cingulate, ␤ = −0.12, P = 0.66). Age was therefore included as a covariate in analysis of variance (ANOVA) in the above analysis. Even though the BDNF abnormality might indeed be correlated with schizophrenia, neuroleptic treatment was a potential cause of the abnormality, and needed to be evaluated in the present study. To assess any influence of haloperidol, a typical neuroleptic, which was preferentially administered to the patients, the drug was given chronically to adult rats (Figure 2) . BDNF levels were measured in the three brain regions, hippocampus, cingulate cortex and frontal cortex. Haloperidol had no effect on BDNF levels in all the brain regions examined.
Chronic application of BDNF has been reported to down-regulate its high-affinity receptor TrkB in brain neurons and desensitize further BDNF signaling. 18 To determine levels of TrkB protein, we carried out Western blot analysis for the hippocampus as well as for the prefrontal cortex. Expression of TrkB protein was detected as a specific 145-kDa band, consistent with the apparent molecular size of non-truncated TrkB receptors. TrkB immunoreactivity in the hippocampus was significantly lower in the schizophrenics than in the controls (43.9% decrease, P Ͻ 0.05, ANOVA) ( Figure 3 ). Consistent with this finding, correlation analysis by the Pearson's product moment method (Figure 4) . However, similar reduction in TrkB levels was found in the prefrontal cortex as well. The prefrontal area of schizophrenic patients contained a significant lower level (43 ± 23%) of TrkB protein, compared to the control (100 ± 18%) (P Ͻ 0.05, F[1, 16] = 8.00), although the statistical correlation between TrkB and BDNF levels was not apparent in this region.
To investigate further the deficit in the BDNF/TrkB activity in schizophrenics, we measured the protein levels of calbindin-D, whose expression is maintained and up-regulated by BDNF 11, 20 Immunoblots revealed the presence of a specific 28-kDa band, corresponding to the authentic size of calbindin-D (Figure 3) . Levels of calbindin-D in the hippocampus of schizophrenics were significantly decreased in comparison with controls (37.9% decrease, P Ͻ 0.05). Expression of neuronspecific enolase (NSE) was measured in parallel as a control neuronal marker. There was no significant difference in the levels of NSE, suggesting the specificity of the phenotypic changes. The observed decline in calbindin-D protein, as well as the down-regulation of TrkB receptors, confirmed the impairment of the BDNF/TrkB activity in schizophrenia.
Discussion
Using two-site EIAs, we demonstrated that BDNF levels were significantly elevated in the hippocampus (2.3-fold increase, P Ͻ 0.001) and anterior cingulate cortex (1.7-fold increase, P Ͻ 0.01) of schizophrenics compared to those in controls. Previous pathological examinations have indicated that several changes in molecular markers appear to represent the effects of neuroleptic treatment rather than schizophrenic pathology itself. 21, 22 Thus, one of the major concerns in the present postmortem study had been the possibility that the BDNF increase in schizophrenic patients might reflect neurochemical changes that were induced by medical treatment. However, there was no clear dissociation of BDNF distribution between neuroleptictreated and neuroleptic-withdrawn patients in the present study (see Figure 1a) . Moreover, chronic treatment of a typical neuroleptic failed to alter BDNF protein concentrations in the hippocampus of rats. This view is also supported by independent animal data demonstrating that chronic treatment of rats with haloperidol does not increase, but rather decreases the level of BDNF mRNA in the limbic system. 45 These observations indicate that the increase in BDNF protein in the hippocampus and anterior cingulate cortex is likely to represent a molecular pathological feature of the disease itself, rather than an effect of neuroleptics.
There was a difference in PMI between the two groups, but several lines of evidence indicate that our finding is unlikely to be the result of prolonged PMI in schizophrenics. Multiple regression analysis revealed that PMI did not affect neurotrophin levels in any brain region in either the schizophrenics or control subjects. Moreover, it is quite unlikely that the longer PMI for schizophrenic samples would have led to a region-specific increase in levels of BDNF, but not in those of other neurotrophins. Moreover, it has been demonstrated that PMI (up to 6 h) has no influence on measurable neurotrophin contents. 23 Accordingly, expression of high-affinity BDNF receptor, TrkB, is reduced in the corticolimbic structures of schizophrenics and correlated inversely with BDNF levels in their hippocampus. Although it is uncertain whether the reduction of TrkB receptor resulted from the enhanced release of BDNF in patients or reflected a substantial defect of its regulation in this disease, this evidence for TrkB receptor down-regulation in schizophrenia confirms that neurotrophic signaling of BDNF is indeed impaired in patients.
The expression of BDNF is influenced by various hormones, cytokines and neurotransmitters, among which the strongest positive regulator is suggested to be an excitatory neurotransmitter, glutamate. 24, 25 Is hyperexcitability responsible for the local increase of BDNF in schizophrenic patients? The neural activity of Molecular Psychiatry the hippocampal region evaluated by positron emission tomography varies considerably in schizophrenic patients depending on their symptom profiles, 26, 27 providing no consistent findings about functional activities in this brain region. Neurochemical studies have rather suggested hypofunction of glutamatergic transmission both in schizophrenic models and in patients. 28 In agreement, the psychostimulants, phencyclidine and ketamine, both of which block excitatory NMDA-type glutamate channels, decrease BDNF mRNA expression in the hippocampus of rats and reduce regional cerebral blood flow in this region of the patients, respectively. 29, 30 These observations suggest that upregulation of BDNF in schizophrenia cannot simply be explained by local neuronal excitability.
The activation of TrkB enhances phenotypic differentiation of pyramidal and non-pyramidal neurons, inducing expression of a GABA-synthesizing enzyme (GAD67), 11 neuropeptides, 10,11 calbindin-D. 10, 18 synaptophysin 13 and the AMPA receptor subunits. 15 Interestingly, reduced expression of all these molecules is often associated with schizophrenia [31] [32] [33] [34] [35] [36] [37] and may be ascribed to the down-regulation of TrkB receptors. Recently, another phenotypic marker of GABAergic neurons has been investigated: 38 decreased expression of reelin has been found in schizophrenic patients. 39 In fact, these pathological changes quite resemble the phenomena seen in a reeler mouse. [40] [41] [42] This mouse carries a mutated gene for reelin and displays cortical/hippocampal dysplasia. 43, 44 It is especially noteworthy that overexpression of BDNF in transgenic mice suppresses expression of reelin during brain development and induces aberrant cortical lamination. 9 Such a scenario may be important in the brain malformation found in schizophrenic patients. Taken together, the BDNF/TrkB abnormality observed in schizophrenic patients might provide a molecular basis for both the structural and phenotypic impairments seen in this disease, although this etiological argument is assumptive and remains to be examined experimentally. Future studies should provide an answer to the question of when neurotrophic dysfunction appears and leads to neurochemical or anatomical defects in the corticolimbic structures and how it contributes to the emergence of schizophrenic symptoms.
